SCHEMBL2865173

SCHEMBL2865173

CCOc1ccc(Cc2cc(CP(=O)(O)O)ccc2F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC5A1 P13866 1/20 0.50
SLC5A2 P31639 1/20 0.50
DHFR P00374 1/20 0.42
PTPN1 P18031 1/20 0.40
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
PLK1 P53350 1/20 0.39
MAPT P10636 4/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
PKM P14618 1/20 0.38
FFAR1 O14842 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
KAT6A Q92794 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
THRA P10827 1/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2863706 0.85 SLC5A1 (0.49) SLC5A1SLC5A2DHFRPTPN1PLK1
SCHEMBL2874055 0.84 SLC5A2 (0.51) SLC5A1SLC5A2
SCHEMBL2872112 0.80 ESR1 (0.42) SLC5A1SLC5A2DHFRPTPN1PLK1
SCHEMBL16301967 0.80 NQO1 (0.54) PTPN1PLK1MAPTALDH1A1SMN1; SMN2
SCHEMBL2871388 0.79 SLC5A2 (0.52) SLC5A1SLC5A2DHFRMAOAMAOB
SCHEMBL2874053 0.78 THRA (0.52) SLC5A1SLC5A2PTPN1PLK1MAPT
SCHEMBL17916 0.76 SLC5A2 (0.52) SLC5A1SLC5A2DHFRMAPTALDH1A1
SCHEMBL2860898 0.76 TLR7 (0.40) SLC5A1SLC5A2MAPTSMN1; SMN2KDM4E
SCHEMBL2867993 0.75 SLC5A2 (0.51) SLC5A1SLC5A2PTPN1PLK1MAPT
SCHEMBL2866968 0.73 THRA (0.47) SLC5A1SLC5A2DHFRMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691898-B2 Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US disclosed
US-20080119441-A1 Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
CN-101072783-A Phosphonic acid derivative and therapeutic agent for disease in which high phosphate level in blood participates KOTOBUKI PHARMACEUTICAL CO LTD (JP) 2007-11-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119441-A1 Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia NR0B1, NR0B2, PTH1R SLC5A1 1236/4885SLC5A2 1771/4885DHFR 368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.